Molly He Joins Jim Tananbaum and His Team at Foresite Capital Management
Late April 2017, Foresite Capital reavealed that Dr. Molly He would join Foresite Capital as a venture partner. Molly has vast experience in genomic and pharmaceutical research and development, which spans for over 15 years. Additionally, she previously worked at Illumina as the senior director.
Jim Tananbaum, the CEO and M.D of Foresite Capital, praised Dr. He as one of the most acclaimed scientific researchers in next-generation sequencing. He also reiterated that her vast expertise in drug development and genomics, as well as tremendous leadership track record are useful resources to Foresite. In fact, her skills would be helpful to the company, especially in its endeavors to diversify and expand its portfolio of transformational entities.
At Illumina, Dr. He was tasked with the role of overseeing the company’s worldwide protein reagent enhancements and innovations. Before joining Illumina, she worked at Pacific Biosciences as the head of protein sciences. In the earlier stages of her career, Molly He spent about a decade in the pharmaceutical industry. Aside from her Ph.D. in protein biophysics from LA-based University of California, Molly holds a biochemistry degree from Nankai University.
Jim Tananbaum has created a name for himself in the corporate circles due to his numerous achievements. He holds vast experience spanning for more than two decades, especially in creating healthcare companies. Currently, he is the founder and CEO of Foresite Capital, which has about $1.1 billion in terms of assets under management. Foresite Capital Management combines the healthcare specialization with the best practices of growth investing. Since the company’s establishment, it has been investing in companies with late-stage, disruptive services and products in various sectors of healthcare such as diagnostics and genomics. More details can be found on LinkedIn.
As per Ideamensch, Before the inception of Foresite, Tananbaum served as the CEO and founder of Theravance. He was also a founding partner of Prospect Venture Partners II and III. Early in promising his career, Jim served at Sierra Ventures as a partner. In fact, he played a significant role in the inception of the company’s healthcare service investment practice. Jim is also acknowledged for leading other numerous investments including Jazz Pharmaceuticals (IPO), Healtheon, Amerigroup (IPO), and Amira Phramaceuticals.
You can visit his Crunchbase profile: https://www.crunchbase.com/person/james-tananbaum#/entity